Member Info for cwebb07

A doubling of the SP from here wouldn't be great considering we were at £5 twice over the last 2 yrs.
Appreciate there has been some dilution but given the optimistic outlook around Bex should we not be looking at more?

:-(

Don't get spiked

You know it's coming just don't get spiked

All said and done 2022 will be the year one way or another

I can see the issue of more significant data being the catalyst for the much awaited rerate.
Thus data is what I believe he needs to get the deal he wants.
When and what that is the million dollar question

So a lot of people are asking how about the partnering. We know that this could become a significant partner opportunity, but we don't want to do this yet. We'd like to obtain additional data really to generate the value for the shareholders. I have collected here a few examples. You have heard about CD47 company, EUR 5 billion Pfizer bought another one for EUR 2 billion, anti-CD47 never demonstrated a single agent activity as bexmarilimab has shown.

Then probably down again for the placing that's comings
Rinse and repeat

The BOD tried to reassure shareholders with 2 RNSs which didn't work.
Nothing will push this back up significantly unless it's a cease in hostilities or an update on any sale.
I guess the the update in any sale would need reassurance that payment is not affected by sanctions.
Not much to ask for on both counts ;-)

What a basket case this company is

Thanks Sax
Looking like this is the year we have been waiting for for a few years now.
We were at £5 twce over the last 2 years on much less.
GLA hold for the rise

In old money is that not a BOOM

I think many thought 10€ would be here by now.
Was hoping for £15-£20 a while back so £10 might now be the compromise unless you are prepared to wait much longer.
Did they not say even 10€ might be late 2024

He's doing such a great job

.

Markku has bought a few shares this week.
He must be expecting a SSV period

.

Traumakine will be re-positioned for multiple indications in organ protection together with partnerships

· Near term value inflections are expected from the accelerated development of Bexmarilimab

Says it all really Bex is where its at and Organ protection for T.

Near term value inflections nice to see in black and white

Thanks Boys
Hopefully 2022 is the year

More good news and looks like Farn are building some great info that could make this the year for farn.
Let's not forget plenty of big Investors and IIs are in at a level much higher than today's SP